Navigation Links
Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Date:4/30/2009

TAMPA, Fla., April 30 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that eight presentations related to the Company's products, pipeline and research will be presented at the 2009 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO)

These presentations include data related to Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, fenretinide, and retinal research programs from the Sirion San Diego, CA based drug discovery laboratory.

Durezol (difluprednate ophthalmic emulsion) 0.05% was approved by the U.S. Food & Drug Administration (FDA) after an expedited review in June 2008 for the treatment of post-operative inflammation and pain associated with ocular surgery. A supplemental New Drug Application (sNDA) was filed in December 2008 seeking an approval for Durezol as a treatment for endogenous anterior uveitis based partially on a head to head comparison to Pred Forte(R). The application was accepted in February 2009 by the agency and is under review.

Fenretinide is currently being evaluated in an ongoing phase II clinical trial in the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). The trial is a two year multicenter, randomized, double-masked, placebo controlled, dose-comparison in over 225 patients at 30 sites in the United States. A summary of the preliminary results of a planned interim analysis of this study was provided in a press release made by Sirion on April 15th, 2009. The ARVO presentations on fenretinide contain a more detailed analysis of the data obtained from the interim analysis.

Identified below are the presentations scheduled for the upcoming ARVO meeting.

Dose Uniformity of Prednisolone Acetate Ophthalmic Suspensions Compared to Durezol (difluprednate ophthalmic emulsion) 0.05%

Session Date/Start Time: Monday May 4, 8:30-10:15 am

Posterboard Number: A351 - Program Number: 1461

Durezol Compared to Pred Forte(R) in the Treatment of Endogenous Anterior Uveitis

Session Date/Start Time: Tuesday May 5, 8:30-10:15 am

Posterboard Number: D1106 - Program Number: 2697

Sirion Therapeutics Poster Presentations Featuring Fenretinide

A Phase II Multicenter, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects with Age-Related Macular Degeneration: Preliminary Demographic Data and Reasons for Screen Failure

Session Date/Start Time: Wednesday May 6, 3:45-5:30 pm

Posterboard Number: A451 - Program Number: 4918

A Phase II, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects with Age-Related Macular Degeneration: Baseline Lesion Size, Characteristics, and Preliminary Progression Data

Session Date/Start Time: Wednesday May 6, 3:45-5:30 pm

Posterboard Number: A452 - Program Number: 4919

Sirion Therapeutics Poster Presentations Featuring Retinal Research

Accumulation of Toxic Retinal Fluorophores in Various Degenerative Retinal Diseases

Session Date/Start Time: Wednesday May 6, 8:30-10:15 am

Posterboard Number: A444 - Program Number: 4188

Characterization of Fluorophores in the Diseased Retinal Pigment Epithelium

Session Date/Start Time: Wednesday May 6, 8:30-10:15 am

Posterboard Number: A427 - Program Number: 4171

Anti-Angiogenic Properties of N-(4-hydroxyphenyl) Retinamide in Ocular Tissue

Session Date/Start Time: Sunday May 3, 8:30-10:15 am

Posterboard Number: A43 - Program Number: 56

Fenretinide Ameliorates Retinal Pathology in the Ins2Akita Diabetic Mouse

Session Date/Start Time: Sunday May 3, 8:30-10:15 am

Posterboard Number: A42 - Program Number: 55

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development, and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion Therapeutic, Inc. has a diverse product portfolio which includes products that address ocular diseases and conditions including uveitis, herpetic keratitis, dry eye, and geographic atrophy associated with dry AMD. For more information, please visit http://www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
(Date:12/8/2016)... , 8 de dezembro de 2016  A Mederi Therapeutics Inc . ... um tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). ... ... Live Stretta procedure performed and broadcast during ... at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s ... possible. With this in mind, SIGVARIS has created a new line of anti-embolism ... bed rest and provide the benefits of graduated compression when transitioning from recovery ...
Breaking Medicine News(10 mins):